ClinicalTrials.gg
RecruitingNCT07066137Allena-menteUpdated Nov 3, 2026

Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices

An interventional study of CAREN and Control group in Healthy Individuals (Controls), Parkinson Disease and Multiple Sclerosis, sponsored by IRCCS Centro Neurolesi Bonino Pulejo. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by IRCCS Centro Neurolesi Bonino Pulejo · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled May 2024, registered Oct 2024).
  • Started May 2024; still recruiting 2 years 6 months later.
Updated Nov 3, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo — 6 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · IRCCS Centro Neurolesi Bonino Pulejo.

Planned enrollment
5th of 13
150 · median 60
Started
2024
with 1 other
No phase
13 of 13
6 open now
Registered
8th of 13
by date

Among the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 13 with no phase, and was the 8th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Parkinson Disease by IRCCS Centro Neurolesi Bonino Pulejo, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate motor responses in healthy subjects and patients with movement disorders, brain and spinal cord injury, neuromuscular diseases, or cardiovascular diseases.

This study aims to evaluate the effectiveness of traditional physical activities combined with innovative interventions such as cryotherapy, ultrasound therapy, laser therapy, transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS). It will also assess the impact of proprioceptive stimuli provided by either the immersive virtual reality (CAREN), or visuo-cognitive-motor enhancement (S.V.T.A.), and music therapy.

The main questions it aims to answer are:

How do these interventions affect motor activities and their functional recovery? What are the temporal and spatial changes in activation sequences related to motor learning and maintenance? When there is a comparison group: Researchers will compare outcomes between different intervention arms (e.g., physical activity with advanced devices vs. traditional methods) to find out if the advanced interventions result in better motor control and functional recovery.

Participants will:

  • Undergo various rehabilitation protocols including physical activity and advanced interventions.
  • Be assessed using different tool, such as fMRI, dtMRI, and NIRS to study in vivo neuroimaging and assess changes in brain function and connectivity.
Read the detailed description

Objectives

Primary Objectives Investigating Motor Gesture Control: Study the sensory-motor structures and their connectivity in healthy participants and patients with neurological, cardiovascular, or neuromuscular conditions. This includes analyzing responses to advanced interventions such as transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), and the CAREN (Computer Assisted Rehabilitation Environment) system.

Understanding Central Control Mechanisms: Assess spatial and temporal changes in brain activity during motor training and recovery processes, leveraging advanced neuroimaging techniques (e.g., fMRI, dtMRI, NIRS).

Secondary Objectives Postural Disorder Prevention: Develop strategies to enhance postural stability and prevent related disorders, improving sports performance and the quality of life in patients with neurodegenerative conditions.

Integration of Imaging and Psychometric Data: Employ multimodal data to uncover brain function patterns and inform rehabilitation strategies, contributing to personalized recovery protocols and optimized training methods.

Methodology Study Design

This is an interventional study aimed at evaluating the metabolic, functional, and neurophysiological aspects of motor responses in participants subjected to intensive physical and cognitive training. By combining traditional therapies with innovative technologies (e.g., CAREN, IVS3, AlterG, tDCS, TMS), the study will explore:

Central nervous system activation and connectivity. Temporal and spatial dynamics of motor learning and maintenance. The role of proprioceptive, visual, and auditory inputs in motor coordination.

Phases of Study Phase 1: Recruitment and Baseline Assessments Participants will be recruited through direct communication and provided with detailed study information.

Baseline evaluations will include:

Clinical and medical-sports assessment. Neuropsychological evaluation (e.g., MoCA, TMT, Stroop Test). Postural and gait analysis. Baseline imaging (MRI, EEG). Phase 2: Intervention and Data Collection

Participants will undergo structured interventions:

Physiotherapy sessions combined with neuromodulation techniques. Training on the CAREN system to assess and improve motor and postural functions.

Use of advanced devices for electromyographic data collection, oxygen consumption measurements, and 3D gait analysis.

Imaging and functional assessments will be repeated post-intervention.

Phase 3: Data Analysis and Dissemination Collected data will be anonymized, processed using advanced imaging and statistical algorithms, and analyzed for correlations between training responses and functional recovery.

Results will be published in high-impact international journals. Technologies and Assessments

Neuroimaging Techniques:

Functional and structural MRI (including T1-weighted, T2-weighted, and DTI sequences).

Analysis of mean diffusivity and fractional anisotropy to evaluate white matter integrity.

NIRS to assess cortical hemodynamics during tasks.

Neurophysiological Tools:

EEG and ECG to monitor the electrical activity of the brain and heart. Surface electromyography (EMG) to evaluate muscle activation patterns.

Advanced Rehabilitation Devices:

CAREN system: A virtual environment platform for motor and postural rehabilitation.

Alter-G/Gait Trainer 3 for assisted gait training. IVS3 FLIR system for thermal imaging of muscular activity.

Neuropsychological Assessments:

Comprehensive cognitive evaluation, including MoCA, TMT, Stroop, and PASAT. Auditory anamnesis and visuomotor training (e.g., S.V.T.A.).

Population The study aims to recruit 150 participants, including healthy individuals and patients aged 18-70 years with neurological conditions (stroke, dementia, Parkinson's Disease, Multiple Sclerosis, Spinal Cord Injury). Detailed inclusion and exclusion criteria ensure the selection of suitable candidates.

Ethical and Administrative Aspects All participants will provide informed consent per ethical guidelines (Declaration of Helsinki and GDPR compliance).

The relevant Ethics Committee approves the study, with no additional costs or compensations.

Results will be transparently reported, adhering to international research standards.

03

Conditions studied

  • Healthy Individuals (Controls)
  • Parkinson Disease
  • Multiple Sclerosis
  • Alzheimer Disease
  • Dementia
  • Stroke

Keywords

  • Virtual Reality
  • motor rehabilitation
  • cognitive rehabilitation
  • Functional Recovery
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (MoCA) score (adjusted for age and education) equal to or greater than 20.

Exclusion criteria

Exclusion Criteria:

  • Severe medical and psychiatric disorders potentially affecting the training
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Healthy Subjects

    The subjects will undergo baseline examinations including MRI, spirometry, surface electromyography, 3D gait analysis, postural assessment and stabilometric analysis, O2 consumption measurement, neuropsychological assessment, ECG, and EEG. Subsequently, the healthy subjects (approximately 50) will undergo intensive aerobic and anaerobic training (including sensory-motor-cognitive training) and exercises on the CAREN platform. For the other 25 participants, transcranial magnetic stimulation (TMS)/transcranial direct current stimulation (tDCS) and music therapy will be added.

    Other: Control group

  • Experimental
    Experimental group

    As for the neurological patients (50), they will undergo posture and gait rehabilitation using the CAREN platform, while the other 25 will receive additional enhancement through non-invasive neuromodulation. This constitutes the other arm of the study.

    Device: CAREN

Interventions

  • DeviceCAREN

    The interventions include proprioceptive stimuli combined with specific rehabilitation protocols, such as Tabata training, plyometric training, and visual-cognitive-motor enhancement with the S.V.T.A. method. Healthy subjects and athletes (about 50) will participate in intensive aerobic and anaerobic training, including sensory-motor-cognitive training and exercises on the CAREN platform. Another 25 participants will have TMS/tDCS and music therapy added to their regimen. Regarding neurological patients, 50 participants will undergo posture and gait rehabilitation using the CAREN platform, while 25 will receive non-invasive neuromodulation to enhance their rehabilitation outcomes. This arm of the study focuses on the recovery of motor and cognitive functions. This study uses the CAREN system as a tool for physical rehabilitation in neurological and healthy participants. The device is not being investigated for new indications and the study is conducted entirely in Italy.

  • OtherControl group

    the control group is typically the group that does not receive the experimental treatment or intervention, serving as a baseline to compare the effects of the intervention. However, in the context you're describing with healthy subjects and athletes, here's how it's structured: Healthy subjects and athletes (around 50 participants) will undergo: Intensive aerobic and anaerobic training Sensory-motor-cognitive training Additionally, 25 of these participants will receive: Transcranial Magnetic Stimulation (TMS) Transcranial Direct Current Stimulation (tDCS) Music therapy This approach allows for a comparison between the effects of the physical and cognitive training alone versus the enhanced effects when combined with neuromodulation (TMS, tDCS) and music therapy. This design will help in assessing the added value of these interventions on performance

06

What researchers measure

Primary outcomes

  1. Amplitude of Motor-Related Event-Related Potentials (ERPs) During Gesture Execution Assessed by EEG.

    Motor-related EEG activity will be recorded during the execution of standardized gestures. The primary outcome is the mean amplitude (in µV) of specific ERP components (e.g., N200, P300) over motor cortex electrodes. Data will be averaged across trials for each participant and reported as group means ± standard deviation. Differences between healthy participants and clinical groups will be assessed using appropriate statistical tests.

    Time frame: Baseline (T0), post-intervention (T1, 12 weeks after baseline), and follow-up (T2, 3 months post-intervention).

Secondary outcomes

  1. Respiratory Exchange Ratio (RER) During Submaximal Exercis

    Metabolic efficiency will be assessed through the respiratory exchange ratio (RER = VCO₂/VO₂) during submaximal steady-state exercise. RER will be measured at standardized workload levels and summarized as mean ± SD. Comparisons between groups or timepoints will assess changes in substrate utilization patterns.

    Time frame: Baseline (T0), post-intervention (T1, 12 weeks after baseline), and follow-up (T2, 3 months post-intervention).

  2. Change in Global Cognitive Function as Measured by MoCA Total Score

    Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). The primary outcome is the change in total score (range: 0-30) from baseline to post-intervention. Data will be summarized as mean ± SD and analyzed using paired or independent statistical tests, depending on the study design.

    Time frame: Baseline (T0), post-intervention (T1, 12 weeks after baseline), and follow-up (T2, 3 months post-intervention).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bonanno M, De Pasquale P, De Marchis C, Lombardo Facciale A, Paladina G, Fonti B, Quartarone A, Calabro RS. Might patients with cerebellar ataxia benefit from the Computer Assisted Rehabilitation ENvironment (CAREN)? A pilot study focusing on gait and balance. Front Bioeng Biotechnol. 2024 Jun 24;12:1385280. doi: 10.3389/fbioe.2024.1385280. eCollection 2024. PubMed 39011156 ↗
  • De Pasquale P, Bonanno M, Lombardo Facciale A, Maggio MG, Thaut MH, Hurt C, Quartarone A, Impellizzeri F, Calabro RS. Can neurologic music therapy make the difference when using immersive virtual reality in Parkinson disease motor training? Promising findings from a secondary analysis. Front Rehabil Sci. 2026 Feb 26;7:1707528. doi: 10.3389/fresc.2026.1707528. eCollection 2026. PubMed 41835097 ↗

Individual participant data

Plan to share: Yes — we plan to share individual participant data (IPD) with other researchers. The data will be made available through a secure platform, ensuring participant confidentiality and compliance with ethical guidelines. Access will be granted under a data use agreement that requires anonymization and outlines permitted uses. We encourage collaborative research and publication of findings derived from the shared data for a period of five years following the study's completion.

Supporting information: Statistical analysis plan, Clinical study report

Time frame: Individual participant data (IPD) and supporting information will be available starting at the commencement of the study and will remain accessible for five years.

Access criteria: Access to individual participant data (IPD) and supporting information will be granted to qualified researchers, including academic institutions, healthcare organizations, and other entities involved in neurorehabilitation research. Researchers will be able to access the anonymized IPD, study protocols, and relevant supporting information such as assessment measures and data collection methods. Access will be facilitated through a secure online data-sharing platform, where approved users can download the data after signing a data use agreement that outlines the terms of use and ensures compliance with ethical guidelines and participant confidentiality. This process aims to promote collaboration while safeguarding the integrity and privacy of the participants involved in the study.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2028, 55 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 55 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion May 2026 → Dec 2028 and completion Dec 2026 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Jul 15, 2025
StartActual
May 5, 2024
Primary completionEst.
Dec 6, 2028was May 2026
CompletionEst.
Dec 31, 2028was Dec 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 3, 2026
Sites
IRCCS Centro Neurolesi Bonino Pulejo is now Recruiting
Nov 3, 2026
Primary completion
May 5, 2026→Dec 6, 2028
Nov 3, 2026
Study completion
Dec 31, 2026→Dec 31, 2028
Nov 3, 2026
Eligibility
Maximum age 60 Years→70 Years
Nov 3, 2026
Contact
Study contact now listed: added m•••@irccsme.it · •••8250. See the current contact
Nov 3, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • IRCCS Centro Neurolesi Bonino Pulejo · Messina, ItalyContact added r•••@irccsme.it · •••8133Contact added (no phone or email listed)
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Active, not recruiting→Recruiting
    IRCCS Centro Neurolesi Bonino Pulejo is now Recruiting
    Primary completion May 5, 2026→Dec 6, 2028
    Study completion Dec 31, 2026→Dec 31, 2028
    Eligibility Maximum age 60 Years→70 Years
    Contact Study contact now listed: added m•••@irccsme.it · •••8250. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • IRCCS Centro Neurolesi Bonino Pulejo · Messina, ItalyContact added r•••@irccsme.it · •••8133Contact added (no phone or email listed)
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07066137
Lead sponsor
IRCCS Centro Neurolesi Bonino Pulejo
Responsible party
Rocco Salvatore Calabrò (MED, PhD, IRCCS Centro Neurolesi Bonino Pulejo) — Principal investigator
First posted
Jul 15, 2025
Start date
May 5, 2024
Primary completion
Dec 6, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Maria Grazia Maggio, Phd
Contact
mariagrazia.maggio@irccsme.it
+3909061128250
Rocco Salvatore Calabrò, PhD
study director · IRCCS Centro Neurolesi Bonino Pulejo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion